These are the groups the article says a provider should identify before starting therapy so monitoring can be set up in advance
The incidence varies considerably between different medications and doses: Semaglutide (Ozempic): Vomiting occurs in approximately 5-10% of patients at diabetes doses Semaglutide (Wegovy): At the higher weight management dose (2.4mg), vomiting affects up to 16% of patients Liraglutide (Victoza): Vomiting affects approximately 5% of patients Liraglutide (Saxenda): At weight management doses, vomiting occurs in about 7-10% of patients Dulaglutide (Trulicity): Vomiting affects approximately 7-9% of patients Tirzepatide (Mounjaro): Vomiting occurs in approximately 5-10% of patients, varying by dose These side effects are most pronounced during the initial treatment phase, particularly in the first 48 weeks, and often diminish as the body adapts to the medication
We'll discuss your goals and create a plan to help you begin your successful weight loss journey.
Wang J, Dudman NPB, and Wilcken DEL (1993)
The legal landscape may shift, potentially affecting availability of compounded options
Yes it's a prescription, and it's all possible because of a form of progesterone hormone called Norethindrone Acetate